диссертации / 66

111

62.Schneider MA, Skinner RB, Rosenberg EW, et al. Serologic determination of Helicobacter pylori in rosacea patients and controls/ M.A.Schneider, R.B.Skinner, E.W. Rosenberg// Clin Res. - 1992. – Vol.4. – P.831A.

63.Sharma VK, Lynn A, Kaminski M. et al. A study of the prevalence of Helicobacter pylori and other makers of upper gastrointestinal tract disease in patients with rosacea/ V.K. Sharma, A.Lynn, M.Kaminski// Am J Gastroenterol. - 1998. – Vol.93. – P.220-222.

64.Jones MP, Knable A Jr, White MJ, et al. Helicobacter pylori in rosacea: lack of an association (letter)/ M.P.Jones, A. Knable Jr, M.J.White// Arch Dermatol. - 1998. – Vol.134. – P.511.

65.Shaubert J, Gallo R.L. Antimicrobial peptides and the skin immune defense system/ J. Shaubert, R.L. Gallo// J Allergy Clin Immunol. - 2008. – Vol.122(2). –P.261-266.

66.Gallo R.L., Yamasaki K, Kanada K et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes/ R.L.Gallo,

cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid/ S.Morizane, K.Yamasaki, F.D.Kabigting// J Invest Dermatol. - 2010. – Vol.130. – P.1297-1306.

68.Yamasaki K, Di Nardo A, Bardan A et al. Incresed serine protease activity and cathelicidin promotes skin inflammation in rosacea/ K.Yamasaki, A.Di Nardo, A.Bardan// Nat Med. – 2007. – Vol.13. – P.975-980.

69.Shibata M, Katsuyama M, Onodera T et al. Glucocorticoids enhance Toll-like recetor 2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines/ M.Shibata, M.Katsuyama, T.Onodera// J

Invest Dermatol. - 2009. – Vol.129. – P.375-382.

70.Powell FC. What’s going on in rosacea/ F.C. Powell// J Eur Acad Dermatol Venereol. - 2000. – Vol.14(5). – P.351-352.

71.Kendall SN. Remission of rosacea induced by reduction of gut transit time/ S.N.Kendall// Clin Exp Dermatol. – 2004. – Vol.29. – P.297-299.

112

72.Steigleder GK. Dermatologie und Venerologie/ G.K.Steigleder. - Stuttgart: Thieme, 1975. – P.476-481.

73.Wilkin JK. Rosacea. Pathophysiology and Treatment/ J.K. Wilkin// Arch Dermatol. - 1994. – Vol.130. – P.359-362.

74.Plewig G, Kligman AM. Akne und Rozacea/ G.Plewig, A.M.Kligman. - Berlin: Springer-Verlag, 1994. – 740 p.

75.Wilkin JK, Dahl M, Detmar M et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Commitee on the classification and staging of rosacea/J.K.Wilkin, M.Dahl, M.Detmar// J Am Acad Dermatol. – 2004. – Vol.50. – P.907-912.

76.Plewig G, Jansen Th. The Rosacea In Fitzpatrick’s dermatology in General Medicine/ G.Plewig, Th.Jansen. - 5th Ed. – NY, 1999. – P.785-99.

77.Stone DU, Chodosh J. Ocular rosacea: an update on pathogenesis and therapy/ D.U. Stone, J.Chodosh// Curr Opin Ophthalmol. - 2004. – Vol.15. – P.499-502.

78.Bamford J. et al. Rogers Childhood stye and adult rosacea/ J.Bamford// J Am Acad Dermatol. – 2006. – Vol.55. – P.951-955.

79.O’Leary PA, Kierland RR. Pyoderma faciale/ P.A.O’Leary, R.R.Kierland// Arch Dermatol Syph. – 1940. – Vol.41. – P.451.

80.Jansen T, Plewig G. Clinical and histological variants of rhinophyma, including nonsurgical treatment modalities/ T.Jansen, G.Plewig// Facial Plast Surg. - 1998. – Vol.14. – P.241-253.

81.Jansen T et al. Rosacea fulminans triggered by high-dose vitamins B6 and B12/ T.Jansen// J Eur Acad Dermatol Venereol. – 2001. – Vol.15. – P.484-485.

82.Scheinfeld N, Berk T. A review of the diagnosis and treatment of rosacea/ N.Scheinfeld, T.Berk// Postgrad Med. – 2010. – Vol.122. – P.139-143.

83.van Zuuren EJ, Kramer S, Carter B et al. Interventions for rosacea/ E.J.van Zuuren, S.Kramer, B.Carter// Cochrane Database Syst Rev. - 2011 Mar 16. - 3:CD003262.

84.Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications/ A.N.Sapadin, R.Fleischmajer// J Am Acad Dermatol. - 2006. – Vol.54. – P.258-265.

113

85.Fleisher Jr AB, Dinehart S, Stough D et al. Safety and efficacy of a new extended-

release formulation of minocycline/ A.B.Fleisher Jr, S.Dinehart, D.Stough// Cutis. - 2006. – Vol.78 (4 Suppl). – P.21-31.

86.Webster GF. An open label, community-based, 12-week assessment of the

87.Theobald K, Bradshaw M, Leyden J. Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea/

K.Theobald, M.Bradshaw, J.Leyden// Skinmed. – 2007. – Vol.6. – P.221-226.

88.Del Rosso JQ, Shlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus 100 mg doxycycline in the treatment of rosacea/ J.Q.Del Rosso,

J.Shlessinger, P.Werschler// J Drugs Dermatol. – 2008. – Vol.7 – P.573-576.

89.Sloan B, Scheinfeld N. The use and safety of doxycycline hyclate and other second-

generation tetracyclines/ B. Sloan, N.Scheinfeld// Expert Opin Drug Saf. - 2008. – Vol.7. – P.571-577.

90.Bakar O, Demircay Z, Yuksel M. et al. The effect of azithromycin on reactive oxygen species in rosacea/ O.Bakar, Z.Demircay, M.Yuksel// Clin Exp Dermatol. -

2007. - Vol.32. – P.197-200.

91.Kim JH, Oh YS, Choi EH. Oral azithromycin for treatment of intractable rosacea/ J.H.Kim, Y.S.Oh, E.H.Choi// J Korean Med Sci. – 2011. – Vol.26(5). – P.694-696.

92.Rebora A. Management of rosacea/ A.Rebora// Am J Clin Dermatol. - 2002. – Vol.317. – P.489-496.

93.Rosso J. A status report on management of rosacea/ J.Rosso// Cutis. - 2002. –

Vol.170. – P.271-275.

94.Akamatsu H, Oguchi M, Nishijima S. et al. The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne/ H.Akamatsu, M.Oguchi, S.Nishijima// Arch Dermatol Res. - 1990. – Vol.282(7). – P.449-454.

114

95.Jansen T, Plewig G. Pathogenesis and therapy of rosacea/ T.Jansen, G.Plewig// Fortschr Med. – 1996. – Vol.114(35-36). – P.494-496.

96. Jansen T, Regele D, Schirren CG et al. Persistent erythema and edma of the face associated with rosacea and lymph vessel dysplasia/ T.Jansen, D.Regele, C.G.Schirren// Hautarzt. – 1998. – Vol.49(12). – P. 932-935.

97.Fender AB, Ignatovich Y, Mercurio MG. Pyoderma faciale/ A.B.Fender, Y.Ignatovich, M.G.Mercurio// Cutis. – 2008. – Vol.81. – P.488-490.

98.Sobottka A, Lehman P. Rosacea 2009: new advances in pathophysiology, clinical staging and therapeutic strategies/ A.Sobottka, P.Lehman// Hautarzt. - 2009. – Vol.60. – P.999-1009.

99.Gollnick H, Matthies C, von der Weth R. Double-blind, double-dummy, randomized, placebo-controlled, five-armed, multicenter phase II/III study to evaluate the efficacy and safety of different concentrations of isotretinoin versus doxycycline in the treatment of rosacea, subtype II and III/ H.Gollnick, C.Matthies, R.von der Weth// J Am Acad Dermatol. - 2010. - Vol. AB41. – P.1162.

100.Pelle K. et al. Rosacea: Therapy/ K.Pelle// J Am Acad Dermatol. – 2004. – Vol.51 – P.499-512.

101.Slawson D. Permetrin cream useful in the treatment of rosacea/ D.Slawson// Am J Fam Physician. – 2003. – Vol.67. – P.1782,1784.

102.Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis/ U.Wollina// Am J Clin Dermatol. – 2007. – Vol.8. – P.157-173.

103.Chu CY. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid induced rosacea-like eruption/ C.Y.Chu// J Eur Acad Dermatol Venereol. – 2007. – Vol.21. –P.484-490.

104.Kevin K, Russ B, Bostrom P. Pimecrolimus for treatment acne rosacea/ K.Kevin, B.Russ, P.Bostrom// SKINmed. – 2005. – Vol.4. – P.147-150.

105.Cuncha P, Rossi A. Pimecrolimus cream 1% is effective in a case of granulomatous rosacea/ P.Cuncha, A.Rossi// Acta Derm Venereol. – 2006. – Vol.86.

– P.71-72.

115

106.Ogunleye T, James WD. Ethanol-induced flushing with topical pimecrolimus use/ T.Ogunleye, W.D.James// Dermatitis. – 2008. - 19:E1-2.

107.Serdar ZA, Yasar S. Efficacy of 1% terbinafine cream in comparison with 0,75% metronidazole gel for the treatment of papulopustular rosacea/ Z.A.Serdar, S.Yasar// Cutan Ocul Toxicol. – 2011. – Vol.30(2). – P.124-128.

108.Hawkins SS, Subramanyan K, Liu D. et al. Cleansing, moisturizing,and sunprotection regimens for normal skin, self-perceived sensitive skin, and dermatologist-assessed sensitive skin/ S.S.Hawkins, K.Subramanyan, D.Liu// Dermatol Ther. - 2004. - 17(Suppl 1). – P.63-68.

109.Laqueize S, Czernieleski J, Baltas E. Beneficial use of Cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea/ S.Laqueize, J.Czernieleski, E.Baltas// J Dermatol Treat. - 2007. – Vol.18. – P.158-162.

110.Wu JJ, Weinstein GD, Kricorian GJ, et al. Topical kinetin 0,1% lotion for improving the signs and symptoms of rosacea/ J.J.Wu, G.D.Weinstein, G.J.Kricorian// Clin Exp Dermatol. - 2007. – Vol.32. – P.693-695.

111.Ortiz A, Elkeeb L, Truitt A, et al. Topical PRK 124(0,125%) lotion for improving the signs and symptoms of rosacea/ A.Ortiz, L.Elkeeb, A.Truitt// J Drugs Dermatol. - 2009. – Vol.8. – P.459-462.

112.Weber TM, Ceilley RI, Buerger A, et al. Skin tolerance, efficacy, and quality of life of patients with red facial skin using a skin care regimen containing Licochalone A/ T.M.Weber, R.I.Ceilley, A.Buerger //J Cosmet Dermatol. – 2006. – Vol.5. – P.227-232.

113.Gupta AK, Chaudhry MM. Rosacea and its management: an overview/ A.K.Gupta, M.M.Chaudhry// J Eur Acad Dermatol Venereol. - 2005. – Vol.19. – P.273-285.

114.Jansen T, Plewig G. The treatment of rosaceous lymphoedema/ T.Jansen, G.Plewig// Clin Exp Dermatol. - 1997. – Vol.22. – P.57.

115.Capote R, Alonso-Lebrero JL, Garcia F, et al. Polypodium leucotomos extract inhibits trans-urocanic acid photoisomerization and photodecomposition/ R.Capote,

116

J.L.Alonso-Lebrero, F.Garcia// J Photochem Photobiol B. - 2006. – Vol.82. – P.173-

179.

116.Gonsalez S, Alonso-Lebrero JL, Del Rio R, et al. Polypodium leucotomos extract: a nutraceutical with photoprotective properties/ S.Gonsalez, J.L.AlonsoLebrero, R.Del Rio// Drugs Today (Barc). - 2007. – Vol.43. – P.475-485.

117.Bernstein EF. The pulsed-dye laser for treatment of cutaneous conditions/ E.F. Bernstein. - G Ital Dermatol Venereol. – 2009. – Vol.144. – P.557-72.

118.Myers P, Bowler P, Hills S. A retrospective study of the efficacy of intense pulsed light for the treatment of dermatologic disorders presenting to a cosmetic skin clinic/ P.Myers, P.Bowler, S.Hills// J Cosmet Dermatol 2005. – Vol.4. – P.262-266.

119.Bernstein EF, Kligman A. Rosacea treatment using the new-generation, highenergy, 595 nm, long pulse-duration pulsed-dye laser/ E.F.Bernstein, A.Kligman// Laser Surg Med. – 2008. – Vol.40. – P.233-239.

120.Neuhaus IM, Zane LT, Tope WD. Comparative efficacy of nonpurpuragenic pulsed dye laser and intense pulsed light for erythematotelangiectatic rosacea/ I.M.Neuhaus, L.T.Zane, W.D.Tope// Dermatol Surg. - 2009. – Vol.35. - 920-928.

121.Larson AA, Goldman MP. Recalcitrant rosacea successfully treated with multiplexed pulsed dye laser/ A.A.Larson, M.P.Goldman// J Drugs Dermatol. - 2007. – Vol.6. – P.843-845.

122.Kim TG, Roh HJ, Cho SB, et al. Enhancing effect of pretreatment with topical niacin in the treatment of rosacea-associated erythema by 585-nm pulsed dye laser in Koreans: a randomized, prospective, split-face trial/ T.G.Kim, H.J.Roh, S.B.Cho// Br J Dermatol. – 2011. - Vol.164(3). -573-579.

123.Klaber R. Psychological factors in the aetiology of certain skin diseases/ R.Klaber// Br J Dermatol Syph. – 1947. – Vol.59 (1). – P.1-6.

124.Choczaj-Kukula A, Kwasniewska J. Current possibilities of using antimycotic drugs in the treatment of various skin disorders/ A.Choczaj-Kukula, J.Kwasniewska// Wiad Parazytol. – 2004. – Vol.50(2). – P.125-33.

125.Aizawa H, Niimura M. Oral spironolactone therapy in male patients with rosacea/ H.Aizawa, M.Niimura// J Dermatol. – 1992. – Vol.19(5). – P.293-297.

117

126.Wilkin JK. Rosacea/ J.K.Wilkin// Int J Dermatol. – 1983. – Vol.22(7). – P.393400.

127.Wollina U. The response of erythematous rosacea to ondansteron/ U.Wollina// Br J Dermatol. – 1999. – Vol.140. – P.561-562.

128.Dahl MV, Katz HI, Krueger GG, et al. Topical metronidazole maintains remissions of rosacea/ M.V.Dahl, H.I.Katz, G.G.Krueger// Arch Dermatol. - 1998. – Vol.134. – P.679-683.

129.Beutner KR, Lemke S, Calvarese B. A look at the safety of metronidazole 1% gel: cumulative irritation, contact sensitization, phototoxicity and photoallergy potential/ K.R.Beutner, S.Lemke, B.Calvarese// Cutis. – 2006. – Vol.77(Suppl). – P.12-17.

130.Shalita A, Leyden J. Mechanism-based selection of pharmacologic agents for rosacea/ A.Shalita, J.Leyden// Cutis. – 2004. – Vol.73(1 Suppl). – P.15-18.

131.van Zuuren EJ, Graber MA, Hollis S, et al. Interventions for rosacea/ E.J.van Zuuren, M.A.Graber, S. Hollis// Cochrane Database Syst Rev. – 2005. -CD003262.

132.van Zuuren EJ, Gupta AK, Gover MD, et al. Systemic review of rosacea treatments/ E.J.van Zuuren, A.K.Gupta, M.D.Gover// J Am Acad Dermatol. - 2007.

– Vol.56. – P.107-115.

133.van Zuuren EJ, Kramer S, Carter B, et al. Interventions for rosacea/ E.J.van Zuuren, S.Kramer, B.Carter// Cochrane Database Syst Rev. – 2011. - 3:CD003262.

134.Thiboutot DM, Fleisher Jr AB, Del Rosso JQ, et al. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea/ D.M.Thiboutot, A.B.Fleisher Jr, J.Q.Del Rosso// J Drugs Dermatol. - 2008. – Vol.7. – P.541-546.

135.Yentzer B, Fleisher A. Changes in rosacea comorbidities and drug utilization over time/B.Yentzer, A.Fleisher// J Am Acad Dermatol. - 2010. – Vol.AB37. – P.1144.

136.Gupta A, Gover M. Azelaic acid (15% gel) in the treatment of acne rosacea/ A.Gupta, M.Gover// Int J Dermatol. – 2007. Vol.1. – P.1-6.

137.Gollnick H, Layton A. Azelaic acid 15% gel in the treatment of rosacea/ H.Gollnick, A. Layton// Expert Opin Pharmacother. – 2008. – Vol.9(15). – P.26992706.

118